(Q37399078)

20 August 2017

1 reference

title

A preliminary benefit-risk assessment of varenicline in smoking cessation (English)

1 reference

20 August 2017

1 reference

Kate Cahill

1

1 reference

20 August 2017

Lindsay Stead

series ordinal

2

1 reference

20 August 2017

Tim Lancaster

series ordinal

3

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

32

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

119-135

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200932020-00005

20 August 2017

exact match

0 references

cites work

Measures of abstinence in clinical trials: issues and recommendations

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932020-00005

Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness

21 January 2018

1 reference

12 December 2020

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

1 reference

12 December 2020

Outcome criteria in smoking cessation trials: proposal for a common standard.

1 reference

12 December 2020

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

1 reference

12 December 2020

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

1 reference

12 December 2020

Epidemiology of tobacco use and dependence

1 reference

12 December 2020

Smoking and suicidal behaviors in the National Comorbidity Survey: Replication

1 reference

12 December 2020

Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors

1 reference

12 December 2020

Preventing tobacco use among young people. A report of the Surgeon General. Executive summary

1 reference

12 December 2020

Cytisine for smoking cessation: a literature review and a meta-analysis

1 reference

12 December 2020

Advances in pharmacotherapy for tobacco dependence.

1 reference

12 December 2020

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

1 reference

12 December 2020

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

1 reference

12 December 2020

Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes

1 reference

12 December 2020

Development of a rational scale to assess the harm of drugs of potential misuse

1 reference

12 December 2020

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

12 December 2020

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

1 reference

12 December 2020

Neurobiology of nicotine addiction: implications for smoking cessation treatment

1 reference

12 December 2020

Motivating and helping smokers to stop smoking

1 reference

12 December 2020

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

12 December 2020

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

1 reference

12 December 2020

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

1 reference

12 December 2020

Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation

1 reference

12 December 2020

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

1 reference

12 December 2020

Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.

1 reference

12 December 2020

Cigarette smoking among adults--United States, 2006

1 reference

12 December 2020

Nicotine receptor partial agonists for smoking cessation

1 reference

12 December 2020

10.2165/00002018-200932020-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1034069376

0 references

1 reference